Application of a High-Resolution Melt Assay for Monitoring SARS-CoV-2 Variants in Burkina Faso and Kenya
Caitlin Greenland-Bews,Sonal Shah,Morine Achieng,Emilie S. Badoum,Yaya Bah,Hellen C. Barsosio,Helena Brazal-Monzó,Jennifer Canizales,Anna Drabko,Alice J Fraser,Luke Hannan,Sheikh Jarju,Jean-Moise Kaboré,Mariama A. Kujabi,Maia Lesosky,Jarra Manneh,Tegwen Marlais,Julian Matthewman,Issa Nebié,Eric Onyango,Alphonse Ouedraogo,Kephas Otieno,Samuel S. Serme,Sodiomon Sirima,Ben Soulama,Brian Tangara,Alfred Tiono,William Wu,Abdul Karim Sesay,Issiaka Soulama,Simon Kariuki,Chris Drakeley,Feiko O ter Kuile,Emily R Adams,David J Allen,Thomas Edwards
DOI: https://doi.org/10.1101/2024.04.11.24305244
2024-04-16
Abstract:The rapid emergence and global dissemination of SARS-CoV-2 highlighted a need for robust, adaptable surveillance systems. However, financial and infrastructure requirements for whole genome sequencing (WGS) mean most surveillance data have come from higher-resource geographies, despite unprecedented investment in sequencing in low-middle income countries (LMICs) throughout the SARS-CoV-2 pandemic. Consequently, the molecular epidemiology of SARS-CoV-2 in some LMICs is limited, and there is a need for more cost-accessible technologies to help close data gaps for surveillance of SARS-CoV-2 variants. To address this, we have developed two high-resolution melt curve (HRM) assays that target key variant-defining mutations in the SARS-CoV-2 genome, which give unique signature profiles that define different SARS-CoV-2 variants of concern (VOCs). Extracted RNA from SARS-CoV-2 positive samples collected from 205 participants (112 in Burkina Faso, 93 in Kenya) on the day of enrolment in the MALCOV study (Malaria as a Risk Factor for COVID-19) between February 2021 and February 2022 were analysed using our optimised HRM assays and compared to Next Generation Sequencing (NGS) on Oxford Nanopore MinION . With NGS as a reference, two HRM assays, HRM-VOC-1 and HRM-VOC-2, demonstrated sensitivity/specificity of 100%/99.29% and 92.86/99.39%, respectively, for detecting Alpha, 90.08%/100% and 92.31%/100% for Delta and 93.75%/100% and 100%/99.38% for Omicron. The assays described here provide a lower-cost approach (<$1 per sample) to conducting molecular epidemiology, capable of high-throughput testing. We successfully scaled up the HRM-VOC-2 assay to screen a total of 506 samples from which we were able to show the replacement of Alpha with the introduction of Delta and the replacement of Delta by the Omicron variant in this community in Kisumu, Kenya. These assays are readily adaptable and can focus on local epidemiological surveillance questions or be updated quickly to accommodate the emergence of a novel variant or adapt to novel and emerging pathogens.
Infectious Diseases (except HIV/AIDS)